An interview with Dr. Michael Zasloff, Founder and CEO of Enterin Inc about the company’s vision and goals for treating Parkinson’s disease, autism, and other neurological conditions by repairing a dysfunctional gut-brain axis. Dr. Zasloff gives us deeper insight into Enterin’s lead drug and how it might help patients suffering from these neurodegenerative conditions.
Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Enterin is pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease.
The company’s lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. Enterin is now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease.
For the latest information on Enterin and our current clinical studies, please visit www.enterininc.com